(S)-(+)-4-苄基-3-丙酰-2-恶唑 N-酮, 99%

(S)-(+)-4-BENZYL-3-PROPIONYL-2-OXAZOLIDI N-ONE

(S)-4-苄基恶唑烷-2,5-二酮, 98%

L-Phe-NCA

(R)-N-Boc-2,2-二甲基噁唑烷-4-甲醛, ≥98%

(R)-N-Boc-2,2-dimethyloxazolidine-4-carbaldehyde

(S)-(-)-3-BOC-4-甲氧羰基-2,2-二甲基-1,3-恶唑烷, 99%

Methyl (S)-(-)-3-Boc-2,2-dimethyl-4-oxazolidinecarboxylate

(R)-4-异丙基-2-恶唑烷酮, 99%

(R)-(+)-4-Isopropyl-2-oxazolidinone

(R)-4-苯基-2-恶唑烷酮, 99%

(R)-(-)-4-Phenyl-2-oxazolidinone

(S)-4-(4-氨基苄基)-1,3-噁唑烷-2-酮, 99%

(S)-4-(4-Aminobenzyl)-2(1H)-oxazolidinone

(S)-4-异丙基-2-恶唑烷酮, 99%

(S)-(-)-4-Isopropyl-2-oxazolidinone

(S)-4-苯基-2-恶唑烷酮, 98%

(S)-(+)-4-Phenyl-2-oxazolidinone

(1S,4S,5R)-3,3-二苄基-6,8-二氧杂双环[3.2.1]辛-4-醇, >98.0%(GC)

(1S,4S,5R)-3,3-Dibenzyl-6,8-dioxabicyclo[3.2.1]octan-4-ol

(R)-[2-溴甲基-3-甲基丁基]-1-甲氧基-2-(3-甲氧基丙氧基)苯, 96%

2-(3-Methoxypropoxy)-4-((R)-2-(bromomethyl)-3-methylbutyl)-1-methoxybenzene

(S)-(-)-N-(α-甲基苄基)邻氨甲酰苯甲酸, ≥99%(T)

(S)-(-)-N-(α-Methylbenzyl)phthalamic Acid

(3S,5R,E)-甲基 7-(3-(4-氟苯基)-1-异丙基-1H-吲哚-2-基)-3,5-二羟基庚-6-烯酸酯, 99%

(3S,5R,E)-Methyl 7-(3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl)-3,5-dihydroxyhept-6-enoate

N-异丁酰基-L-巯基丙氨酸, 98%

N-Isobutyryl-L-cysteine for chiral derivatization

(R)-5-溴-3-(1-甲基-2-吡咯烷基甲基)-1H-吲哚, 98%

(R)-5-Bromo-3-[(1-methyl-2-pyrrolidinyl)methyl]-1H-indole

孕烯羧酸内酯, 98%

(7a,17a)-17-羟基-3-氧代-孕甾-4,9(11)-二烯-7,21-二羧酸 gamma-内酯甲酯

(S)-2-(6-羟基萘-2-基)丙酸, 分析对照品, 99%

O-Desmethylnaproxen

(4R,5S)-(+)-4-甲基-5-苯基-2-噁唑烷酮, ≥98%

(4R,5S)-(+)-4-Methyl-5-phenyl-2-oxazolidinone

(S)-4-叔丁基-2-噁唑烷酮, 99.9%

(S)-4-tert-Butyl-2-oxazolidinone

(R)-(+)-N,N-二甲基-1-苯基乙胺, 99%

(R)-(+)-N,N-Dimethyl-1-phenylethylamine